Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma.

Nikhil I KhushalaniMelinda VassalloJudith D GoldbergZeynep ErogluYounchul KimBiwei CaoRobert FergusonKelsey R MonsonTomas KirchhoffCarol M AmatoPaulo BurkeAnn StrangeEmily MonkGeoffrey Thomas GibneyRagini KudchadkarJoseph MarkowitzAndrew S BrohlAnna PavlickAlison RichardsDavid M WoodsJeffrey S Weber

Published in: Journal for immunotherapy of cancer (2022)

NCT01176474 and NCT02970981.

Keyphrases

phase ii
clinical trial
open label
lymph node
phase iii
randomized controlled trial
double blind
prognostic factors
study protocol